SPRY logo

SPRYARS Pharmaceuticals Inc

$9.30
$0.53
(5.62%)
Today
Closed $8.90
$0.40
(4.49%)
After Hours
Updated: 07:29 PM EDT
Reported EarningsMay 15
Mkt Cap$936.43M
Vol1.85M
News
all
press releases
ARS Pharmaceuticals Q1 Earnings Call Highlights
ARS Pharmaceuticals Q1 Earnings Call Highlights...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript
read more...
Benzinga
News Placeholder
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.09% and +2.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.read more...
Benzinga
News Placeholder
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -50.00% and +8.48%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates
Merck KGaA (MKKGY) delivered earnings and revenue surprises of +31.11% and +3.89%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Cronos Group (CRON) Q1 Earnings Meet Estimates
Cronos (CRON) delivered earnings and revenue surprises of 0.00% and +6.94%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +23.94% and +7.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
ARS Pharmaceuticals (SPRY) Projected to Post Quarterly Earnings on Wednesday
ARS Pharmaceuticals (NASDAQ:SPRY) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
<
1
2
...
>